http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2543834-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5d5bb9b9a6d998b72b154ceb1895a3f5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F7-0812 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-706 |
| filingDate | 2005-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_965b1034459df75653550eac363383b4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1941d58a52b5223db6c0b496cc7635c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_faf7be8fc00275086d86bec570b3a837 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_365ab2acd9b0578a0aff1f61b40edccf |
| publicationDate | 2015-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2543834-T3 |
| titleOfInvention | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections and intermediates for their production |
| abstract | A compound that includes a heterocyclic nucleotide base attached to a first carbon atom of a saturated or monounsaturated heterocyclic group, optionally substituted, selected from tetrahydrofuranyl, tetrahydrothienyl, dihydrofuranyl and dihydrothienyl and which also includes a phosphonoalkoxy or phosphonothioalkyl group attached to a second carbon atom of said five-link saturated or monounsaturated heterocyclic group, said first carbon atom being adjacent to the heteroatom of said five-link saturated or monounsaturated heterocyclic group, and said second carbon atom being neither adjacent to the heteroatom nor to the first carbon atom of said five-link saturated or monounsaturated heterocyclic group, said compound being represented by one of the general formulas (II) and (XIX): ** Formula ** wherein: - X1, X2, X3, X4 and X5 are each independently selected from the group consisting of oxygen and sulfur, - B is a natural or synthetic heterocyclic nucleotide base, - R1 and R2 are each independently selected from the group consisting of hydrogen; (-PO3R16) m- PO3R17R18; I rent; alkenyl; alkynyl; cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; arylalkyl, heterocyclic; heterocyclic alkyl; acyloxyalkyl; acyloxyalkenyl; acyloxyalkynyl; acyloxyaryl; acyloxyarylalkyl; acyloxyarylalkenyl; acyloxy-arylalkyl; dialkylcarbonate; alkylaryl carbonate; alkyl alkenylcarbonate; alkylalkylcarbonate; alkenyl carbonate; alkylarylcarbonate; alkenyl alkylcarbonate; dialkenylcarbonate; dialkylcarbonate; wherein said alkyl, alkenyl and alkynyl optionally contain one or more heteroatoms in the hydrocarbon chain or at the end thereof, said heteroatoms being selected independently from the group consisting of oxygen, sulfur and nitrogen; - R3, R4, R5 and R6 are each independently selected from the group consisting of hydrogen, azido, halogen, cyano, alkyl, alkenyl, alkynyl, SR14 and OR14; - R7 and R8 are both hydrogen; - R14 is selected from hydrogen; I rent; alkenyl; alkynyl; cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; heterocyclic; arylalkyl; heterocyclic alkyl; acyloxyalkyl; wherein said alkyl, alkenyl and alkynyl optionally contain one or more heteroatoms in the hydrocarbon chain or at the end thereof, said heteroatoms being selected independently from the group consisting of oxygen, sulfur and nitrogen; - R16, R17 and R18 are independently selected from the group consisting of hydrogen; I rent; alkenyl; alkynyl; cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; arylalkyl; heterocyclic ring; heterocyclic alkyl ring; acyloxy-alkyl; wherein said alkyl, alkenyl and alkynyl optionally contain one or more heteroatoms in the hydrocarbon chain or at the end thereof, said heteroatoms being selected independently from the group consisting of oxygen, sulfur and nitrogen; - X4 and R1, or X5 and R2 can together form an amino acid or polypeptide moiety in which a carboxyl function of said amino acid residue that is at a distance from the amidate nitrogen no greater than 5 atoms is esterified; - X4 and R1 or X5 and R2 together can form a group having the formula -OC (R9) 2OC (O) Y (R10) a where Y> = N or O, a> = 1 when Y is O and> = 1 or 2 when Y is N; - R9 is selected from the group consisting of hydrogen, alkyl, aryl, alkenyl, alkynyl, alkenyl, alkylaryl or alkylaryl, wherein each of said alkyl, alkenyl, alkynyl and aryl groups is optionally substituted with one or more selected atoms or groups from the group consisting of halo, cyano, azido, nitro and OR14; - R10 is selected from the group consisting of hydrogen, alkyl, aryl, alkenyl, alkynyl, alkenyl, alkylaryl and alkylaryl, wherein each of said alkyl, alkenyl, alkynyl and aryl groups is optionally substituted with one or more selected atoms or groups from the group consisting of halo, cyano, azido, nitro, OR14 and NR11R12; - R11 and R12 are each independently selected from the group consisting of hydrogen and alkyl, provided that at least one of R11 and R12 is not hydrogen; - n is an integer representing the number of methylene groups between X2 and P, each of said methylene groups being optional and independently substituted with one or two substituents selected from the group consisting of halogen, hydroxyl, sulfhydryl and C1- alkyl. 4, and selecting n from 1, 2, 3, 4, 5 and 6; and - m is 0 or 1, including its pharmaceutically acceptable salts, solvates and stereoisomers. |
| priorityDate | 2004-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 629.